BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
相关临床试验
9
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2007
进行中（未招募）
4
44.4%
已完成
4
44.4%
招募中
1
11.1%
暂无批准数据
- BioAtla's Board of Directors has launched a formal process to explore strategic options including asset sales, licensing deals, and partnerships to maximize shareholder value. - The company is implementing a significant restructuring plan with approximately 70% workforce reduction and expanded cost-containment measures to reduce operating expenses. - BioAtla will continue its Phase 1 clinical study of BA3182 T-cell engager while maintaining a robust pipeline including Phase 3 ozuriftamab vedotin for OPSCC treatment. - The biotechnology company has engaged Tungsten Advisors as exclusive strategic financial advisor, though no assurance exists that the process will result in transactions.
- BioAtla announced a $40 million special purpose vehicle transaction with GATC Health to advance ozuriftamab vedotin (Oz-V) into Phase 3 development for second-line oropharyngeal squamous cell carcinoma. - The company will receive an initial $5 million by January 2026 for general operations and clinical trial expenses, with the remaining $35 million expected to close in Q1 2026 when the registrational study begins. - BioAtla will retain 65% ownership of Oz-V across all solid tumor indications while leading Phase 3 trial execution through data readout for potential accelerated approval. - Oz-V targets ROR2, a receptor that drives tumor progression and regulates cellular senescence, with potential applications extending to all HPV-positive cancers representing a market opportunity exceeding $7 billion worldwide.
- BioAtla announced agreements for up to $22.5 million in flexible financing, including $7.5 million in pre-paid advances and up to $15 million in standby equity purchases to support operations. - The company is in advanced stages to finalize a strategic transaction with a potential partner and remains on track to complete the deal by year end. - The financing provides operational momentum while BioAtla works to complete its strategic partnership, which management believes will unlock significant value for shareholders. - BioAtla's pipeline includes ozuriftamab vedotin, a Phase 3-ready antibody drug conjugate with FDA Fast Track designation for head and neck cancer, and BA3182, a bispecific T-cell engager in Phase 1 trials.
- BioAtla presented first-in-human Phase 1 data for BA3182, a dual-conditionally active bispecific T-cell engager targeting EpCAM and CD3, showing tumor reductions in five patients across different adenocarcinoma types. - The trial enrolled 39 heavily pretreated patients with metastatic adenocarcinoma, demonstrating generally low-grade and manageable adverse events with dose escalation continuing at 1.2 mg weekly subcutaneous dosing. - Two colorectal carcinoma patients achieved prolonged progression-free intervals of 11 and 14 months, while objective tumor size reductions ranged from 8% to 25% across colorectal, breast, cholangiocarcinoma, and lung cancers. - The dual-CAB technology platform showed greater than 100-fold improvement in therapeutic index compared to non-CAB variants in preclinical studies, potentially addressing over one million patients globally.
- BioAtla's Tab-cel demonstrated an overall response rate in heavily pretreated head and neck cancer patients, with 11 responses out of 29 evaluable patients. - The FDA granted Fast Track designation to Tab-cel, underscoring its potential to address significant unmet needs in this challenging cancer type. - BioAtla anticipates initiating pivotal trials for both Tab-cel and its CTLA-4 program in 2025, with the Tab-cel trial expected to begin first. - The company plans to advance one program independently while seeking a partner for the other, managing cash flow effectively to support pivotal studies.
- BioAtla's ozuriftamab vedotin Phase 2 trial shows a 9-month median overall survival in heavily pretreated head and neck cancer patients, indicating potential efficacy. - Evalstotug combined with PD-1 demonstrates tumor reduction in all first-line melanoma patients, including one complete response, with favorable tolerability. - The company's cash position of $56.5 million, along with recent licensing revenue, is projected to fund operations into early 2026, ensuring continued development. - FDA provides actionable feedback on pivotal trials for ozuriftamab vedotin and evalstotug, potentially leading to registrational trials in 2025.
- Context Therapeutics has acquired the exclusive worldwide license to BioAtla's BA3362, a Nectin-4 x CD3 T-cell engager (TCE), for up to $133 million, including upfront and milestone payments. - BA3362 leverages BioAtla's Conditionally Active Biologics (CAB) platform, designed to enhance anti-tumor potency while minimizing off-target toxicities by targeting Nectin-4. - BioAtla will receive up to $133 million, including $15 million upfront and in near-term milestones, plus potential clinical, development, and commercial milestones, and tiered royalties on net sales. - The acquisition aligns with Context Therapeutics' strategy to expand its pipeline of TCE assets, with first-in-human studies for BA3362 expected to begin in approximately 18 months.
- BioAtla's evalstotug (BA3071), a conditionally active anti-CTLA-4 biologic, demonstrates potential in treating advanced solid tumors, with updated Phase 1 study results to be presented at SITC 2024. - Evalstotug is designed to enhance safety and efficacy compared to traditional CTLA-4 inhibitors by reducing systemic toxicity and enabling combination therapies with checkpoint inhibitors. - BioAtla will also present data on evalstotug at the Society for Melanoma Research 21st International Congress, highlighting its potential for high exposure and extended dosing. - These presentations underscore BioAtla's CAB technology's ability to develop more selective and effective antibody therapeutics for solid tumors, with ongoing clinical trials.
